2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2904

Efficacy and Tolerance of TNF Alpha Inhibitor (TNFI) Treatment in Cardiac Sarcoidosis (CS)
Abstract Number: 2599

Efficacy and Toxicity of Antimalarials in Systematic Lupus Erythematosus: A Systematic Review
Abstract Number: 315

Efficacy of a Wearable-Enabled Physical Activity Counselling Program for People with Knee Osteoarthritis
Abstract Number: 516

Efficacy of Adding Iguratimod Therapy in Rheumatoid Arthritis　Patients Who Had Inadequate Response to Biologic Dmards
Abstract Number: 2154

Efficacy of an Intensive 24-Week Physiotherapy Programme in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data from a Single-Center Controlled Study
Abstract Number: 1694

Efficacy of an Intensive 24-Week Physiotherapy Programme in Scleroderma Patients – Preliminary Data from a Single-Center Controlled Study
Abstract Number: 1556

Efficacy of Biologics and New Anti-Inflammatory Agents Used in the Treatment of Active Psoriatic Arthritis: Systematic Literature Review and Network Meta-Analysis of the Evidence.
Abstract Number: 1048

Efficacy of Educating Visiting Pharmacists Regarding Drug Administration for Patients with Rheumatoid Arthritis Who Poorly Adhere to Treatment Regimens
Abstract Number: 2455

Efficacy of Etanercept in Elderly Patients with Rheumatoid Arthritis
Abstract Number: 2305

Efficacy of Function-Based Exercise Program on Functional Ability, Pain and Quality of Life in Children with Juvenile Idiopathic Arthritis
Abstract Number: 1112

Efficacy of High Dose Versus Moderate Dose Prednisone in the Treatment of Acute Gout
Abstract Number: 425

Efficacy of Monotherapy of the Biologic Dmards in Patients with Rheumatoid Arthritis: Real Life Data from the Hong Kong Biologics Registry
Abstract Number: 1687

Efficacy of Rituximab for Connective Tissue Disease-Associated Interstitial Lung Disease: A Single Center Study of 28 Patients
Abstract Number: 2470

Efficacy of Sarilumab in Combination with Csdmards in Patients with Rheumatoid Arthritis and Inadequate Response to TNF Inhibitors By Baseline Levels of Disease Activity
Abstract Number: 2468

Efficacy of Sarilumab in Patients with Rheumatoid Arthritis Who Previously Received Sarilumab or Tocilizumab

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].